Former Boston Scientific, Medtronic Executive Joins FineHeart’s Board

FineHeart has appointed Pierre Chauvineau to its Board of Directors. Chauvineau joins the board at a strategic stage in the company’s development, as it simultaneously accelerates its clinical and industrial programs for an advanced heart failure treatment and prepares the next phases of its international expansion.

“We are delighted to welcome Pierre Chauvineau to our Board of Directors, which is fully committed to supporting FineHeart’s development strategy,” Board Chairman Jean-Luc Boulnois said. “His profile complements a highly engaged governance team dedicated to advancing FineHeart’s ambitions. His international medtech experience, deep understanding of the cardiovascular sector, and expertise in international market access challenges will be valuable assets in supporting the company’s scale-up.”

With a recognized profile within the international medtech ecosystem, extensive cardiovascular sector expertise, and a track record in supporting companies through structuring, acceleration, and scale-up phases, Chauvineau’s arrival further strengthens FineHeart’s governance, according to executives.

“Pierre’s arrival marks an important step in supporting our clinical, industrial, and international ambitions,” FineHeart Co-Founder/CEO Arnaud Mascarell stated. “With FlowMaker at the core of our strategy, we are developing highly differentiated proprietary technology building blocks—including transcutaneous wireless energy and data transfer, implantable electronics, intelligent physiological control, and associated digital technologies—whose potential could extend to other applications in the field of active implantable medical devices. Pierre’s experience in bringing innovative medical technologies to market will be particularly valuable for FineHeart.”

With more than 35 years of experience gained within major corporations and high-growth innovative companies, Chauvineau’s career combines operational expertise, strategic vision, leadership, and support for innovative companies in medical technologies and value creation within highly regulated environments. Throughout his career, Chauvineau has held senior executive leadership roles at Boston Scientific, Medtronic, and Cameron Health, leading large-scale international operations—including one of Boston Scientific’s largest European business units—and contributing to the global launch of medical technologies.

Chauvineau also has extensive governance experience and a strong track record in supporting rapidly growing companies. He chairs several boards of directors in the medtech and digital health sectors, including Sequana Medical, and actively collaborates with executives, investors, and European innovation programs.

“I am impressed by the quality of the team, the strategic vision driven by FineHeart’s management, and the complementarity of the existing Board of Directors,” Chauvineau commented. “FlowMaker embodies an exceptional technological and medical ambition aimed at addressing a major clinical need that remains largely unmet. I am delighted to contribute to its success alongside the management team and the board.”

FineHeart is a French medical device company focused on creating technologies in the cardiovascular field. Its patented invention, the FlowMaker, is a novel, wirelessly powered, fully implantable mechanical circulatory support device that optimizes cardiac output while preserving the heart’s innate contractility. It is a therapy for long-term circulatory assistance in patients with severe heart failure.

FineHeart was founded by a team of internationally renowned cardiac surgeons and cardiologists, led by Dr. Stephane Garrigue (The FlowMaker inventor) and Dr. Philippe Ritter (co-inventor of cardiac resynchronization therapy), as well as managers with specific expertise in the medical device industry.